Geistlich, a Swiss-based expert in regenerative medicine, specializes in the research and development of regenerative materials for bone and soft tissue. Its flagship products, Bio-Oss and Bio-Gide, are globally recognized in the dental field and have become industry benchmarks in guided tissue regeneration. As part of its expanding global strategy, Geistlich is actively strengthening its presence in China to reinforce its leadership in bone regeneration.
In recent years, China’s oral healthcare market has grown rapidly, accompanied by the rise of competitive domestic brands. Against this backdrop, international professional brands face an increasingly dynamic and competitive landscape. For Geistlich, a pressing challenge lies in consistently projecting a clear, distinctive brand image that resonates in the local market—making brand renewal a strategic imperative.
To facilitate its expansion in the Chinese market, Geistlich China partnered with LABBRAND, the brand naming expert, to enhance its localization naming and communication strategy. Through precise naming, unified messaging, and activation of brand assets, the initiative aims to craft a strong and relevant brand image that is firmly rooted in the Chinese market context.
Drawing on insights into medical materials industry trends and market dynamics, LABBRAND worked with Geistlich across three strategic dimensions—brand leadership, brand experience, and brand influence—to build a differentiated brand expression system tailored to the Chinese market.
For brand leadership, LABBRAND emphasized Geistlich’s technical expertise and professional authority in regenerative medicine, introducing the brand proposition “有所专，自不凡 (Specialized, therefore extraordinary).” The brand positioning echoes and localizes the global slogan “Exactly like no other”, reinforcing Geistlich’s image as an irreplaceable expert in the Chinese market.
For brand experience, we optimized communication efficiency and reduced comprehension barriers through a concise, powerful, and systematically unified Chinese naming system for the product portfolio. This enhanced recognizability and professional trust among both medical professionals and patients.
For brand influence, LABBRAND supported Geistlich in reshaping its semantic assets in China by combining a systematic naming strategy with the new Chinese brand name “盖士通 (gàishìtōng)” and the parent brand “盖氏 (gàishì).” Through the reshaping process, we created a brand language that is both international in character and easy to communicate, laying a solid foundation for Geistlich’s future communication implementation and market expansion.
Building on the overarching brand upgrade strategy, LABBRAND developed a systematic naming system for Geistlich that aligns with pharmaceutical industry standards while ensuring consistency and clarity across all brand touchpoints. The parent brand “盖氏 (Geistlich)” reinforces authority and heritage, while the localized sub-brand “盖士通 (gàishìtōng)” balances phonetic alignment with positive semantic meaning: “盖” (gài) continues the brand’s historical legacy, “士” (shì) represents the gathering of talent, and “通” (tōng) signifies recovery and connectivity.
For Geistlich’s five major product series, LABBRAND also developed a concise, clear, and family-oriented naming scheme to ensure consistency and differentiation across products, significantly enhancing the professionalism and communication effectiveness of the overall brand system.
Through the brand upgrade, Geistlich has established a clearer brand identity system and a more efficient communication foundation in the Chinese market. A unified naming strategy and brand proposition have strengthened its presence in professional channels and provided a standardized framework for future marketing initiatives. In addition, LABBRAND developed an annual communication planning blueprint, supporting Geistlich’s evolution from a “bone regeneration expert” to a recognized “leader in regenerative medicine.” This collaboration not only enhances Geistlich’s linguistic and strategic assets but also reinforces its long-term leadership in China’s increasingly competitive regenerative medicine sector.
To improve your experience, we use cookies to provide social media features, offer you content that targets your particular interests, and analyse the performance of our advertising campaigns. By clicking on “Accept” you consent to all cookies. You also have the option to click “Reject” to limit the use of certain types of cookies. Please be aware that rejecting cookies may affect your website browsing experience and limit the use of some personalised features.
